Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 58% Improvement Relative Risk c19early.org/c Gavrielatou et al. Vitamin C for COVID-19 ICU Favors vitamin C Favors control
Effect of Vitamin C on Clinical Outcomes of Critically Ill Patients With COVID-19: An Observational Study and Subsequent Meta-Analysis
Gavrielatou et al., Frontiers in Medicine, doi:10.3389/fmed.2022.814587
11 Feb 2022    Source   PDF   Share   Tweet
Retrospective 113 consecutive mechanically ventilated COVID+ ICU patients in Greece, 10 receiving high dose IV vitamin C, showing lower mortality with treatment, without statistical significance (p=0.11).
The associated meta analysis includes only 11 studies, while there are currently 56 studies, 33 with mortality results. Authors only include critical patients, however not all studies with critical patients are included, for example [Hamidi-Alamdari, Majidi, Yüksel, Özgünay]. The meta analysis also uses unadjusted results, while PSM, Cox proportional hazards, or KM results are reported by [Al Sulaiman, Gao, Zhang, Zheng]. For [Zhang] authors use 28 day mortality, while the study reports longer term in-hospital mortality.
risk of death, 58.0% lower, RR 0.42, p = 0.11, treatment 2 of 10 (20.0%), control 49 of 103 (47.6%), NNT 3.6.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gavrielatou et al., 11 Feb 2022, retrospective, Greece, peer-reviewed, 10 authors, study period 21 October, 2020 - 8 March, 2021, average treatment delay 5.5 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit